Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page


Bladder cancer cells' migration and proliferation are suppressed by EDARADD silencing.

Maybelline Frensik*

Bladder cancer could be a quite common malignant cancer within the urinary apparatus. The expression of EDARADD (ectodysplasin-A receptor-associated death domain) in bladder cancer is beyond the conventional samples. However, its role in bladder cancer remains unknown. Within the gift study, we tend to analyze the expression of EDARADD in eighty one bladder cancer samples by assay additionally as its correlation with clinical characteristics. Additionally, the role of EDARADD was additionally explored through loss of perform. Cell proliferation assay and MTT assay were conducted to assess the proliferation of bladder cancer cells and trans well assay and wound healing assay were conducted to assess the migration of bladder cancer cells. On the opposite hand, the degree of epithelialmesenchymal transition (EMT) associated proteins and therefore the key molecules within the MAPK sign pathway were detected by western blot. in vivo experiments were additionally conducted to see the impact of EDARADD silencing on the metastasis of bladder cancer cells and therefore the MAPK sign pathway.

Keywords: Bladder cancer; Metastasis; Proliferation; Liquid biopsy; Biomarker; Diagnosis; Cancer research

Published Date: 2022-10-27; Received Date: 2022-09-29